Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) EBIT (2016 - 2025)

Historic EBIT for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $2.1 million.

  • Protalix BioTherapeutics' EBIT fell 4660.49% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 17148.31%. This contributed to the annual value of $3.9 million for FY2024, which is 6255.26% down from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' EBIT is $2.1 million, which was down 4660.49% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' EBIT ranged from a high of $20.4 million in Q2 2023 and a low of -$9.2 million during Q2 2021
  • Moreover, its 5-year median value for EBIT was -$2.5 million (2023), whereas its average is -$1.0 million.
  • In the last 5 years, Protalix BioTherapeutics' EBIT tumbled by 30919.64% in 2021 and then surged by 46967.78% in 2023.
  • Protalix BioTherapeutics' EBIT (Quarter) stood at -$5.7 million in 2021, then surged by 56.27% to -$2.5 million in 2022, then tumbled by 125.05% to -$5.6 million in 2023, then skyrocketed by 228.39% to $7.2 million in 2024, then tumbled by 70.44% to $2.1 million in 2025.
  • Its EBIT stands at $2.1 million for Q3 2025, versus $1.2 million for Q2 2025 and -$4.1 million for Q1 2025.